Skip to main content
Top
Published in: Lung 2/2009

01-04-2009

Association Between p53 codon 72 Genetic Polymorphism and Tobacco Use and Lung Cancer Risk

Authors: Dante D. Cáceres, Luis A. Quiñones, Jane C. Schroeder, Leonel D. Gil, Carlos E. Irarrázabal

Published in: Lung | Issue 2/2009

Login to get access

Abstract

Lung cancer (LCa) is the leading cause of death by cancer in men. Genetic and environmental factors play a synergistic role in its etiology. We explore in 111 lung cancer cases and 133 unrelated noncancer controls the gene-environment interaction (G × E) between p53cd72 polymorphism variants and smoking and the effect on LCa risk in two kinds of case-control designs. We assessed the interaction odds ratio (IOR) using an adjusted unconditional logistic model. We found a significant and positive interaction association between Pro* allele carriers and smoking habits in both case-control and case-only designs: IOR = 3.90 (95% confidence interval [CI] = 1.10–13.81) and 3.05 (95% CI = 1.63–5.72), respectively. These exploratory results suggest a synergistic effect of the smoking habit and the susceptibility of the Pro allele on lung cancer risk compared with each risk factor alone.
Literature
1.
go back to reference Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (1997) Cancer Incidence in five continents, vol VII, No 143. Lyon, France: IARC Scientific Publications Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (1997) Cancer Incidence in five continents, vol VII, No 143. Lyon, France: IARC Scientific Publications
2.
go back to reference Boffeta P, Trichopoulos D (2002) Prostate cancer. In: Adami HO, Hunter D, Trichopoulos D (eds) Textbook of cancer epidemiology. Oxford University Press, New York, pp 400–428 Boffeta P, Trichopoulos D (2002) Prostate cancer. In: Adami HO, Hunter D, Trichopoulos D (eds) Textbook of cancer epidemiology. Oxford University Press, New York, pp 400–428
3.
go back to reference Alberg AJ, Samet JM (2003) Epidemiology of lung cancer. Chest 123(1 Suppl):21S–49S Alberg AJ, Samet JM (2003) Epidemiology of lung cancer. Chest 123(1 Suppl):21S–49S
4.
go back to reference Shields PG (2002) Molecular epidemiology of smoking and lung cancer. Oncogene 21(45):6870–6876 Shields PG (2002) Molecular epidemiology of smoking and lung cancer. Oncogene 21(45):6870–6876
5.
go back to reference Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253(5015):49–53 Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253(5015):49–53
6.
go back to reference Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88(3):323–331 Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88(3):323–331
8.
go back to reference Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC (1999) Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 187(1):8–18PubMedCrossRef Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC (1999) Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 187(1):8–18PubMedCrossRef
9.
go back to reference Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19(2):1092–1100 Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19(2):1092–1100
10.
go back to reference Wang YC, Chen CY, Chen SK, Chang YY, Lin P (1999) p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 5(1):129–134PubMed Wang YC, Chen CY, Chen SK, Chang YY, Lin P (1999) p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 5(1):129–134PubMed
11.
go back to reference Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, Honn SE, Spitz MR (1995) Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 16(9):2205–2208PubMedCrossRef Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, Honn SE, Spitz MR (1995) Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 16(9):2205–2208PubMedCrossRef
12.
go back to reference To-Figueras J, Gene M, Gomez-Catalan J, Galan C, Firvida J, Fuentes M, Rodamilans M, Huguet E, Estape J, Corbella J (1996) Glutathione-S-transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 5(5):337–342PubMed To-Figueras J, Gene M, Gomez-Catalan J, Galan C, Firvida J, Fuentes M, Rodamilans M, Huguet E, Estape J, Corbella J (1996) Glutathione-S-transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 5(5):337–342PubMed
13.
go back to reference Tagawa M, Murata M, Kimura H (1998) Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small-cell lung carcinoma: association with clinicopathological features. Cancer Lett 128(1):93–99PubMedCrossRef Tagawa M, Murata M, Kimura H (1998) Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small-cell lung carcinoma: association with clinicopathological features. Cancer Lett 128(1):93–99PubMedCrossRef
14.
go back to reference Birgander R, Sjalander A, Rannug A, Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Beckman G, Beckman L (1995) P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 16(9):2233–2236PubMedCrossRef Birgander R, Sjalander A, Rannug A, Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Beckman G, Beckman L (1995) P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 16(9):2233–2236PubMedCrossRef
15.
go back to reference Weston A, Ling-Cawley HM, Caporaso NE, Bowman ED, Hoover RN, Trump BF, Harris CC (1994) Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis 15(4):583–587PubMedCrossRef Weston A, Ling-Cawley HM, Caporaso NE, Bowman ED, Hoover RN, Trump BF, Harris CC (1994) Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis 15(4):583–587PubMedCrossRef
16.
go back to reference Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S (1993) Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14(6):1085–1089PubMedCrossRef Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S (1993) Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14(6):1085–1089PubMedCrossRef
17.
go back to reference Biros E, Kalina I, Biros I, Kohut A, Bogyiova E, Salagovic J, Stubna J (2001) Polymorphism of the p53 gene within the codon 72 in lung cancer patients. Neoplasma 48(5):407–411PubMed Biros E, Kalina I, Biros I, Kohut A, Bogyiova E, Salagovic J, Stubna J (2001) Polymorphism of the p53 gene within the codon 72 in lung cancer patients. Neoplasma 48(5):407–411PubMed
18.
go back to reference Xiao H, Singh SV (2007) p53 regulates cellular responses to environmental carcinogen benzo[a]pyrene–7,8-diol-9,10-epoxide in human lung cancer cells. Cell Cycle 6(14):1753–1761PubMed Xiao H, Singh SV (2007) p53 regulates cellular responses to environmental carcinogen benzo[a]pyrene–7,8-diol-9,10-epoxide in human lung cancer cells. Cell Cycle 6(14):1753–1761PubMed
19.
go back to reference Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21(48):7435–7451PubMedCrossRef Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21(48):7435–7451PubMedCrossRef
20.
go back to reference Pfeifer GP, Hainaut P (2003) On the origin of G → T transversions in lung cancer. Mutat Res 526(1–2):39–43PubMed Pfeifer GP, Hainaut P (2003) On the origin of G → T transversions in lung cancer. Mutat Res 526(1–2):39–43PubMed
21.
go back to reference Shen YM, Troxel AB, Vedantam S, Penning TM, Field J. Comparison of p53 mutations induced by PAH o-quinones with those caused by anti-benzo[a]pyrene diol epoxide in vitro: role of reactive oxygen and biological selection. Chem Res Toxicol 19(11):1441–1450 Shen YM, Troxel AB, Vedantam S, Penning TM, Field J. Comparison of p53 mutations induced by PAH o-quinones with those caused by anti-benzo[a]pyrene diol epoxide in vitro: role of reactive oxygen and biological selection. Chem Res Toxicol 19(11):1441–1450
22.
go back to reference Irarrazabal CE, Rojas C, Aracena R, Marquez C, Gil L (2003) Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol Lett 144(1):69–76PubMedCrossRef Irarrazabal CE, Rojas C, Aracena R, Marquez C, Gil L (2003) Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol Lett 144(1):69–76PubMedCrossRef
23.
go back to reference de la Calle-Martin O, Romero M, Fabregat V, Ercilla G, Vives J, Yague J (1990) MspI polymorphism of the human p53 gene. Nucleic Acids Res 18(16):4963 de la Calle-Martin O, Romero M, Fabregat V, Ercilla G, Vives J, Yague J (1990) MspI polymorphism of the human p53 gene. Nucleic Acids Res 18(16):4963
24.
go back to reference Korf B (2000) Human genetics: a problem based approach, 2nd edn. Blackwell Science, Cambridge, MA Korf B (2000) Human genetics: a problem based approach, 2nd edn. Blackwell Science, Cambridge, MA
25.
go back to reference Quiñones L, Lucas D, Godoy J, Cáceres D, Berthou F, Varela N, Lee K, Acevedo C, Martínez L, Aguilera AM, Gil L (2001) CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett 174(1):35–44PubMedCrossRef Quiñones L, Lucas D, Godoy J, Cáceres D, Berthou F, Varela N, Lee K, Acevedo C, Martínez L, Aguilera AM, Gil L (2001) CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett 174(1):35–44PubMedCrossRef
26.
go back to reference Botto LD, Khoury MJ (2001) Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond. Am J Epidemiol 153(10):1016–1020PubMedCrossRef Botto LD, Khoury MJ (2001) Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond. Am J Epidemiol 153(10):1016–1020PubMedCrossRef
27.
go back to reference Khoury MJ, Flanders WD (1996) Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case–control studies with no controls. Am J Epidemiol 144(3):207–213PubMed Khoury MJ, Flanders WD (1996) Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case–control studies with no controls. Am J Epidemiol 144(3):207–213PubMed
28.
go back to reference Hosmer DW, Lemeshow S (1992) Confidence interval estimation of interaction. Epidemiology 3(5):452–456PubMedCrossRef Hosmer DW, Lemeshow S (1992) Confidence interval estimation of interaction. Epidemiology 3(5):452–456PubMedCrossRef
29.
go back to reference Poole C (2001) Low P-values or narrow confidence intervals: which are more durable? Epidemiology 12(3):291–294PubMedCrossRef Poole C (2001) Low P-values or narrow confidence intervals: which are more durable? Epidemiology 12(3):291–294PubMedCrossRef
30.
go back to reference STATA (2000) Intercooled STATA for Windows. 7th edn. STATA Corporation, College Station, TX STATA (2000) Intercooled STATA for Windows. 7th edn. STATA Corporation, College Station, TX
31.
go back to reference Miller DP, Liu G, De Vivo I, Lynch TJ, Wain JC, Su L, Christiani DC (2002) Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res 62(10):2819–2823PubMed Miller DP, Liu G, De Vivo I, Lynch TJ, Wain JC, Su L, Christiani DC (2002) Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res 62(10):2819–2823PubMed
32.
go back to reference Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, Christiani DC (2000) The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9(10):1037–1042PubMed Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, Christiani DC (2000) The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9(10):1037–1042PubMed
33.
go back to reference Weston A, Perrin LS, Forrester K, Hoover RN, Trump BF, Harris CC, Caporaso NE (1992) Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev 1(6):481–483PubMed Weston A, Perrin LS, Forrester K, Hoover RN, Trump BF, Harris CC, Caporaso NE (1992) Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev 1(6):481–483PubMed
34.
go back to reference Liu G, Miller DP, Zhou W, Thurston SW, Fan R, Xu LL, Lynch TJ, Wain JC, Su L, Christiani DC (2001) Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 61(24):8718–8722PubMed Liu G, Miller DP, Zhou W, Thurston SW, Fan R, Xu LL, Lynch TJ, Wain JC, Su L, Christiani DC (2001) Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 61(24):8718–8722PubMed
35.
go back to reference Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G, Rzyman W, Jassem J (2006) Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 52(1):9–14 Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G, Rzyman W, Jassem J (2006) Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 52(1):9–14
36.
go back to reference Hu Y, McDermott MP, Ahrendt SA (2005) The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 11(7):2502–2509 Hu Y, McDermott MP, Ahrendt SA (2005) The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 11(7):2502–2509
37.
go back to reference Popanda O, Edler L, Waas P, Schattenberg T, Butkiewicz D, Muley T, Dienemann H, Risch A, Bartsch H, Schmezer P (2007) Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer 55(1):25–34 Popanda O, Edler L, Waas P, Schattenberg T, Butkiewicz D, Muley T, Dienemann H, Risch A, Bartsch H, Schmezer P (2007) Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer 55(1):25–34
38.
go back to reference Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27(1):110–117 Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27(1):110–117
39.
go back to reference Matakidou A, Eisen T, Houlston RS (2003) TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 18(4):377–385PubMedCrossRef Matakidou A, Eisen T, Houlston RS (2003) TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 18(4):377–385PubMedCrossRef
40.
go back to reference Schabath MB, Wu X, Wei Q, Li G, Gu J, Spitz MR (2006) Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 15(1):158–161 Schabath MB, Wu X, Wei Q, Li G, Gu J, Spitz MR (2006) Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 15(1):158–161
41.
go back to reference Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65(20):9582–9587 Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65(20):9582–9587
42.
go back to reference Kuroda Y, Tsukino H, Nakao H, Imai H, Katoh T (2003) p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett 189(1):77–83 Kuroda Y, Tsukino H, Nakao H, Imai H, Katoh T (2003) p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett 189(1):77–83
Metadata
Title
Association Between p53 codon 72 Genetic Polymorphism and Tobacco Use and Lung Cancer Risk
Authors
Dante D. Cáceres
Luis A. Quiñones
Jane C. Schroeder
Leonel D. Gil
Carlos E. Irarrázabal
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Lung / Issue 2/2009
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-008-9133-3

Other articles of this Issue 2/2009

Lung 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.